Caladrius Biosciences Inc. (NASDAQ:CLBS) shares gapped up before the market opened on Thursday . The stock had previously closed at ($3.30), but opened at $0.52. Caladrius Biosciences shares last traded at $5.48, with a volume of 146,185 shares changing hands.

A number of research firms recently issued reports on CLBS. Maxim Group restated a “hold” rating on shares of Caladrius Biosciences in a research report on Saturday, May 14th. Rodman & Renshaw upgraded Caladrius Biosciences to a “buy” rating in a research report on Saturday, April 30th. HC Wainwright upgraded Caladrius Biosciences from a “neutral” rating to a “buy” rating and set a $1.25 price target for the company in a research report on Friday, April 29th. Finally, Zacks Investment Research upgraded Caladrius Biosciences from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a research report on Monday, July 11th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Caladrius Biosciences has a consensus rating of “Buy” and an average target price of $2.83.

The stock’s market cap is $322.29 million. The company has a 50 day moving average price of $5.45 and a 200-day moving average price of $6.16.

In other news, Director Eric Wei sold 87,500 shares of the stock in a transaction that occurred on Friday, July 1st. The stock was sold at an average price of $0.60, for a total value of $52,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Caladrius Biosciences, Inc, formerly NeoStem, Inc, is a clinical-stage biopharmaceutical company. The Company’s clinical program is based on its dendritic cell and cancer cell technology. It is focused on the development of a cancer treatment designed to focus the cells responsible for tumor growth and metastasis, known as cancer or tumor initiating cells (CSCs).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.